Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
Company Directory
QIAGEN
QIAGEN Strasse 1
Hilden 40724
Germany
Qiagen partners Exosome Diagnostics to develop biofluid sample preparation kits for personalized healthcare
24 July, 2013
Qiagen is partnering with Exosome Diagnostics to develop and commercialise high-performance sample preparation kits for the processing of nucleic acids from exosomes.
Qiagen expands biomarker pipeline of personalized healthcare companion diagnostics
03 June, 2013
Qiagen signs two agreements which adds new biomarkers involving glioblastoma, lymphoma and other cancers to Qiagen's expanding portfolio of potential companion diagnostics that is being developed to help doctors use a patient's genomic information to guide treatment decisions.
QIAGEN unveils sample-to-result next-generation sequencing workflow for clinical research and diagnostics
22 February, 2013
QIAGEN unveils an innovative sample-to-result NGS workflow designed to enable the routine use of a breakthrough technology beyond life sciences research in areas such as clinical research and diagnostics.
Qiagen enters companion diagnostics collaboration agreement with Lilly
15 February, 2013
Qiagen enters into a master collaboration agreement with Eli Lilly for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines across all therapeutic areas.
Clarient adopts KRAS companion diagnostic for colorectal cancer
01 February, 2013
Clarient, a GE Healthcare Company and leading provider of cancer laboratory testing services in the USA, adopts the use of QIAGEN's therascreen KRAS RGQ PCR Kit as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
QIAGEN submits companion diagnostic to FDA to to guide treatment with afatinib
17 January, 2013
QIAGEN submits therascreen EGFR RGQ PCR Kit (therascreen EGFR test) to the US Food and Drug Administration (FDA) as a proposed companion diagnostic to guide treatment with afatinib, a new investigational oncology compound developed by Boehringer Ingelheim.
QIAGEN reveals next-generation sequencing initiative to advance routine workflows
07 November, 2012
QIAGEN is launching the first product in the company's initiative to advance routine workflows in next-generation sequencing (NGS) applications.
QIAGEN partners Lepu Medical to provide rapid diagnosis of heart attacks
17 September, 2012
QIAGEN signs an agreement with Lepu Medical Technology (Beijing), a leading medical device company in China, to provide QIAGEN's ESEQuant Lateral Flow System for use in emergency rooms with Lepu's tests for cardiac markers that diagnose acute myocardial infarction (heart attack).
QIAGEN achieves personalized healthcare milestone in USA for colorectal cancer
09 July, 2012
QIAGEN receives US Food and Drug Administration (FDA) approval to market the therascreen KRAS RGQ PCR to provide guidance on the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
Qiagen partners Cardinal Health to offer molecular diagnostic solutions
02 May, 2012
Qiagen is collaborating with Cardinal Health to extend the company's portfolio of laboratory offerings to select US hospitals to include Qiagen automated laboratory systems and test kits for molecular diagnostics.
Qiagen receives FDA clearances for PCR instrument and Influenza A/B assay
18 April, 2012
The US Food and Drug Administration (FDA) grants two 510(k) clearances for Qiagen's real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use (IVD).
Qiagen expands access to HPV screening in China
12 March, 2012
Qiagen plans to expand access to its digene HPV Test across China through a co-marketing agreement with KingMed Diagnostics, China's largest independent laboratory network.
QIAGEN unveils sample preparation automation system
10 January, 2012
QIAGEN launches the QIAensemble Decapper automation system which facilitates the handling of liquid-based cytology and various other types of liquid samples that are processed by clinical laboratories around the world.
Qiagen partners Eli Lilly to develop molecular companion diagnostic
07 September, 2011
Qiagen is entering into a partnership with Eli Lilly for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly.
Qiagen partners Pfizer to develop molecular diagnostic NSCLC test
18 August, 2011
Qiagen is entering into a partnership with Pfizer for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer (NSCLC).
Qiagen and Abbott agree molecular tests for HIV, HCV and HPV
14 October, 2010
Qiagen and Abbott are entering into an agreement that strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada.
Qiagen flexible automated solution sets new standards for molecular testing
03 September, 2010
Qiagen is launching its flexible automated solution QIAsymphony RGQ which is a novel, integrated system that claims to set new standards for molecular testing and incorporates all workflow steps from sample to detection.
Qiagen receives CE Mark for new HPV test
08 July, 2010
Qiagen receives European certification of its careHPV Test to bring human papillomavirus (HPV) testing to public-health programmes in low-resource, developing countries.
Qiagen acquires licence for PI3K biomarker to develop real-time-PCR
10 February, 2010
Qiagen's wholly owned subsidiary DxS acquires the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.
HPV testing is shown to be more effective at preventing cervical cancer
20 January, 2010
Results from a study of more than 90,000 Italian women published by the Lancet Oncology found that testing for high-risk types of the human papillomavirus (HPV) DNA is significantly more effective in preventing invasive cervical cancer than cytology (Pap testing) alone.
Detection kit for swine flu infections
11 September, 2009
A/H1N1 influenza detection kit provide highly sensitive detection and surveillance for swine flu for use outside the USA and within America for research purposes
Qiagen selects Plexus to develop automated screening system for HPV DNA samples
01 June, 2009
Plexus is selected to develop Qiagen's next generation automated screening system for the pre-processing of human papillomavirus (HPV) DNA samples.
Qiagen launches molecular test kit for prenatal diagnostics
26 May, 2009
Qiagen is launching a novel product for extraction of free circulating fragments of tumour- and foetal-derived nucleic acids as well as viral nucleic acids in human blood.
Qiagen and CNCI to set up large-scale cervical cancer screening programme in India
22 April, 2009
Qiagen and the Chittaranjan National Cancer Institute (CNCI) are collaborating to establish the first large-scale cervical cancer screening programme for women in Kolkata, India.
Qiagen's HPV test provides accurate solution for developing regions
22 September, 2008
A study has shown that the new HPV test developed by Qiagen specifically for use in regions of the world with scarce resources is more accurate in identifying women with cervical disease than the current methods (Pap testing and visual inspection) in these countries.
New research shows the benefits of the HPV DNA test
21 May, 2008
Long-term data from a study published in the International Journal of Cancer showed that women screened only with a human papillomavirus (HPV) DNA test are half as likely to develop moderate to severe cervical disease over the next six years as those who get only conventional cytology (the Pap ′smear’).
Qiagen opens new Service Solutions Centre in Singapore to support Asia-Pacific business growth
22 February, 2008
Qiagen has opened a new Service Solutions Centre in Singapore in the Asia-Pacific region to further increase the company’s responsiveness to the information and service requirements of customers in research, applied testing, pharma and molecular diagnostics in the entire Asian-Pacific region including Australia.
Two new Qiagen DNA transfection reagents offer improved transfection efficiency
19 February, 2008
Qiagen has launched the TransFect Protocol Database and two new DNA transfection reagents: Attractene Transfection Reagent and NanoFect Transfection Reagent.
CMM and Qiagen collaborate to discover molecular biomarkers for breast cancer
18 February, 2008
The Center for Molecular Medicine (CMM) is to collaborate with its affiliates and Qiagen to support research focused on discovering molecular biomarkers capable of helping diagnose breast cancer and other women's health issues.
New sample disrupter provides faster access to DNA, RNA and protein
30 January, 2008
Qiagen's new TissueLyser II is a more compact and robust version of the company’s well-established TissueLyser, is a bead mill that rapidly and effectively disrupts up to 48 or 192 samples at the same time.
Qiagen adds cell death control siRNA tool to AllStars RNAi control portfolio
30 January, 2008
Qiagen has added AllStars Hs Cell Death Control siRNA to the company’s AllStars portfolio of RNAi controls.
Qiagen introduces flexible siRNA sets for 54 human gene families
30 January, 2008
Qiagen has introduced FlexiPlate siRNA Gene Family Lists to enable RNAi screening of 54 human gene families.
Qiagen launches new set of functional genomic tools
30 January, 2008
Qiagen has launched the Human Whole Genome siRNA Set V4.0, the Human Druggable Genome siRNA Set V4.0, and subsets for GPCRs, phosphatases, and kinases to enhance the company’s range of high-throughput RNAi solutions.
Qiagen launches new genomic analysis kit
22 January, 2008
Qiagen has launched the REPLI-g FFPE Kit to support the genomic analysis of fixed tissue samples.
New molecular test for hepatitis B is now available to Canadian doctors
20 November, 2007
Qiagen’s artus HBV LC PCR Kit is a new hepatitis B virus (HBV) assay that monitors the viral load of HBV infected patients and is now available to doctors in Canada to help them determine the success of a treatment.
One-step RT-PCR kit delivers faster results on any real-time cycler
03 October, 2007
Qiagen’s QuantiFast Probe RT-PCR Kits have been developed to deliver faster results in real-time one-step RT-PCR with sequence-specific probes, such as TaqMan probes.
Fast-cycling PCR kit offers rapid results
03 October, 2007
Qiagen has added a fast-cycling PCR kit and a fridge storage DNA polymerase to the company’s range of standard, hot-start, multiplex, long-range, and high-fidelity end-point PCR kits.
New kits provide maximal recovery of DNA and RNA from tiny samples
03 October, 2007
Qiagen has introduced two new kits to provide maximal nucleic acid yields from very small cell and tissue samples.
New fridge storage PCR enzyme for unrivalled ease-of-use
03 October, 2007
Qiagen 's new easy-to-use TopTaq DNA Polymerase provides high product yields in a wide range of end-point PCR applications.
Qiagen agrees to distribute Whatman FTA product range and FTA-based kits
22 May, 2007
Whatman and Qiagen have agreed a non-exclusive distribution partnership that provides Qiagen with the right to market and sell Whatman FTA and and FTA-based kits to all Qiagen's target market sectors.
Qiagen introduces novel assay for miRNA targets
08 May, 2007
A pioneering technology that creates a new dimension of capabilities for assays targeting microRNAs (miRNAs) has been introduced by Qiagen.
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo